The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Josef S Smolen, Robert Landewé, Ferdinand C. Breedveld et al. · Annals of the Rheumatic Diseases · 2013 · 1.8K citations · Full text

Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped

Édouard Louis, Jean–Yves Mary, Gwénola Vernier-Massouille et al. · Gastroenterology · 2011 · 589 citations · Full text

Inflammation, Antimetabolite Therapy, Anti-inflammatory +5

The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register

Jennifer Humphreys, Suzanne Verstappen, Kimme L Hyrich et al. · Annals of the Rheumatic Diseases · 2012 · 155 citations · Full text

The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries

Ashok Kumar Jha, Alex Upton, W. Dunlop et al. · Advances in Therapy · 2015 · 146 citations · Full text

Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries

Valentin Brodszky, Petra Baji, Orsolya Balogh et al. · The European Journal of Health Economics · 2014 · 128 citations · Full text

Rheumatoid Disorder, Rheumatology, Epidemiology +10